European Commission Proposal Would Make It Harder for Innovator Companies to Launch Friendly Duplicates (Biosimilars)

Published date17 December 2019
Subject MatterEuropean Commission,EU,Proposed Regulation,Prescription Drugs,Biosimilars,Generic Drugs,Member State,Pharmaceutical Industry,Marketing Authorization Application
AuthorUlf Grundmann,Elisabeth Kohoutek,Geneviève Michaux
Law FirmKing & Spalding

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT